Elevance Health, INC Form 4 insider transactions

Ramiro G Peru, a Director of Elevance Health, Inc., purchased 1,000 shares of common stock on July 17, 2026 for $366.05 per share.

Gail Boudreaux, President and CEO and a Director of Elevance Health, Inc., purchased 2,725 shares of common stock on July 17, 2026.

Elevance Health Director Robert L. Dixon Jr. sold 151 shares of common stock at a price of $401.77 per share.

Ronald W. Penczek, CAO & Controller of Elevance Health, Inc., reported transactions involving the acquisition and disposition of company common stock and employee stock options on May 19, 2026.

Director Deanna D. Strable-Soethout acquired 563 deferred stock units as part of the Elevance Health Board of Directors Compensation Program.

Director Antonio F. Neri acquired 563 deferred stock units as part of the Elevance Health Board of Directors Compensation Program.

Director Bahija Jallal acquired 563 deferred stock units as part of the Elevance Health, Inc. Board of Directors Compensation Program.

Director Robert L. Dixon Jr. acquired 563 deferred stock units as part of the Elevance Health, Inc. Board of Directors Compensation Program.

Director Steven H. Collis acquired 563 deferred stock units as part of the Elevance Health, Inc. Board of Directors Compensation Program.

Elevance Health Director Amy W. Schulman reported a late Form 4 filing detailing the sale of 26 common shares at $287.50 each, attributed to a broker's discretionary authority.

Elevance Health Director Steven H. Collis acquired 3,000 shares of common stock for approximately $869,520, signaling confidence in the company's future.

Elevance Health's CAO and Controller, Ronald W. Penczek, reported the acquisition of restricted stock units and stock options, alongside the disposal of shares for tax liabilities.

Elevance Health's EVP & Chief Legal Officer, Erin M. Wessling, reported acquiring restricted stock units and stock options, alongside a disposition of shares for tax purposes.

Elevance Health's EVP & Chief HR Officer, Ryan R. Craig, reported routine acquisitions of restricted stock units and stock options, alongside dispositions for tax liabilities.

Elevance Health's EVP & Chief Health Benefits Officer, Felicia F. Norwood, reported recent acquisitions of restricted stock units and stock options, alongside stock dispositions for tax liabilities.

Elevance Health's EVP & Chief Digital Info Officer, Ratnakar Lavu, reported recent acquisitions of restricted stock units and stock options, alongside sales to cover tax liabilities.

Elevance Health's EVP & President, Commercial, Charles Morgan Kendrick JR, reported a series of equity transactions including RSU and PSU grants, stock option awards, and tax-related stock dispositions.

Elevance Health EVP Peter D. Haytaian reported the vesting of restricted stock units and subsequent tax-related share dispositions.

Elevance Health President and CEO Gail Boudreaux reported the acquisition of restricted stock units and stock options, alongside dispositions to cover tax liabilities.

Elevance Health Director Amy W. Schulman reported the acquisition of 218 phantom stock units under the company's compensation program.

Elevance Health's EVP & CFO, Mark Kaye, disposed of 2,895 shares of common stock at $340.24 per share to cover tax liabilities from restricted stock vesting.

Elevance Health's EVP & Chief Legal Officer, Erin M. Wessling, disposed of 152 shares of common stock to cover tax liabilities related to restricted stock vesting.

Elevance Health's EVP & Chief Legal Officer, Erin M. Wessling, was granted 931 restricted share units and options to purchase 3,541 shares of common stock.

Elevance Health's EVP & Chief HR Officer, Ryan R. Craig, acquired 970 restricted stock units and 3,690 employee stock options on September 2, 2025.

An Elevance Health director has disclosed a future planned purchase of 1,200 shares of common stock under a Rule 10b5-1 plan.

Elevance Health Director Steven H. Collis was granted 639 phantom stock units as part of the company's Board of Directors Compensation Program, effective August 1, 2025.

Elevance Health's President and CEO, Gail Boudreaux, acquired 8,500 shares of common stock through multiple open market purchases on July 18, 2025, signaling strong insider confidence.

Director Susan D. DeVore reports acquiring deferred stock units and disposing of common stock in Elevance Health, Inc.

Deanna D Strable-Soethout, a director of Elevance Health, Inc., reported the acquisition of deferred stock units under the company's Board of Directors Compensation Program.

Director Ryan M. Schneider reported the acquisition of 601 deferred stock units of Elevance Health, Inc. on May 14, 2025.